Pharmacology of proton pump inhibitors

Current Gastroenterology Reports

Volumn 10, Issue 6, 2008, Pages 528-534

  Shin, Jai Moo ^b   Sachs, George ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; BENATOPRAZOLE; CLARITHROMYCIN; ESOMEPRAZOLE; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; ILAPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; TIMOPRAZOLE;

AREA UNDER THE CURVE; BEDTIME DOSAGE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NONHUMAN; PEPTIC ULCER; PHARMACODYNAMICS; REFLUX ESOPHAGITIS; REVIEW; STOMACH ACID SECRETION; STOMACH PARIETAL CELL; STOMACH PH; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTACIDS; ANTI-ULCER AGENTS; ESOPHAGITIS; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; HUMANS; PARIETAL CELLS, GASTRIC; PEPTIC ULCER; PROTON PUMP INHIBITORS;

EID: 60749128080     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-008-0098-4     Document Type: Review

References (63)

1. Forte JG, Forte TM, Black JA, et al.: Correlation of parietal cell structure and function. J Clin Gastroenterol 1983, 5(Suppl 1): 17-27.
2. Sawaguchi A, Aoyama F, Ide S, et al.: The cryofixation of isolated rat gastric mucosa provides new insights into the functional transformation of gastric parietal cells: An in vitro experimental model study. Arch Histol Cytol 2005, 68: 151-160.
3. Sachs G, Chang HH, Rabon E, et al.: A nonelectrogenic H+ pump in plasma membranes of hog stomach. J Biol Chem 1976, 251: 7690-7698.
4. +)-ATPase. J Biol Chem 1986, 261: 16788-16791.
5. +)-ATPase. Biochem Biophys Res Commun 1988, 157: 203-209.
6. +-ATPase alpha-subunit. Biochim Biophys Acta 1992, 1131: 69-77.
7. +- ATPase. Biochem Biophys Res Commun 1993, 196: 1240-1247.
8. +)- ATPase genes in exon/intron organization but difference in control region. J Biol Chem 1990, 265: 9027-9032.
9. +/ ATP stoichiometry. J Biol Chem 1982, 257: 6296-6299.
10. Munson K, Garcia R, Sachs G: Inhibitor and ion binding sites on the gastric H,K-ATPase. Biochemistry 2005, 44: 5267-5284.
11. +-ATPase. J Biol Chem 2008, 283: 16876-16884.
12. + - transporting ATPase. Proc Natl Acad Sci U S A 1990, 87: 6767-6771.
13. Shull GE: CDNA cloning of the beta-subunit of the rat gastric H,K-ATPase. J Biol Chem 1990, 265: 12123-12126.
14. + - ATPase (proton pump). Proc Natl Acad Sci U S A 1990, 87: 6418-6422.
15. Vagin O, Denevich S, Sachs G: Plasma membrane delivery of the gastric H,K-ATPase: The role of beta-subunit glycosylation. Am J Physiol Cell Physiol 2003, 285: C968-C976.
16. Vagin O, Turdikulova S, Sachs G: The H,K-ATPase beta subunit as a model to study the role of N-glycosylation in membrane trafficking and apical sorting. J Biol Chem 2004, 279: 39026-39034.
17. Vagin O, Turdikulova S, Yakubov I, et al.: Use of the H,KATPase beta subunit to identify multiple sorting pathways for plasma membrane delivery in polarized cells. J Biol Chem 2005, 280: 14741-14754.
18. Munson K, Law RJ, Sachs G: Analysis of the gastric H,K ATPase for ion pathways and inhibitor binding sites. Biochemistry 2007, 46: 5398-5417.
19. Abe K, Kaya S, Taniguchi K, et al.: Evidence for a relationship between activity and the tetraprotomeric assembly of solubilized pig gastric H/ K-ATPase. J Biochem (Tokyo) 2005, 138: 293-301.
20. Shin JM, Grundler G, Senn-Bilfinger J, et al.: Functional consequences of the oligomeric form of the membrane-bound gastric H,K-ATPase. Biochemistry 2005, 44: 16321-16332.
21. Reenstra WW, Crothers J Jr, Forte JG: The conformation of H,K-ATPase determines the nucleoside triphosphate (NTP) selectivity for active proton transport. Biochemistry 2007, 46: 10145-10152.
22. +) ATPase. Nature 1981, 290: 159-161.
23. + - ATPase in vitro and in vivo. Biochem Pharmacol 2006, 71: 837-849.
24. Sachs G, Shin JM, Besancon M, et al.: The continuing development of gastric acid pump inhibitors. Aliment Pharmacol Ther 1993, 7(Suppl 1): 4-12; discussion 29-31.
25. + - ATPase. Biochim Biophys Acta 1993, 1148: 223-233.
26. + - ATPase in vivo. Biochem Pharmacol 2004, 68: 2117-2127.
27. + - adenosinetriphosphatase. Biochemistry 1993, 32: 2345-2355.
28. Shin JM, Sachs G: Restoration of acid secretion following treatment with proton pump inhibitors. Gastroenterology 2002, 123: 1588-1597.
29. + - adenosine triphosphatase alpha subunit and its effect on inhibition of rat gastric acid secretion. Gastroenterology 1995, 109: 1134-1141.
30. Hunt RH, Armstrong D, Yaghoobi M, et al.: Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z. Aliment Pharmacol Ther 2008, 28: 187-199.
31. + - ATPase activity. J Biol Chem 1985, 260: 13681-13684.
32. +) -ATPase in vivo by omeprazole. Biochem Biophys Res Commun 1985, 126: 78-82.
33. Ferron GM, McKeand W, Mayer PR: Pharmacodynamic modeling of pantoprazole's irreversible effect on gastric acid secretion in humans and rats. J Clin Pharmacol 2001, 41: 149-156.
34. Dammann HG, Burkhardt F: PIntoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion. Eur J Gastroenterol Hepatol 1999, 11: 1277-1282.
35. Katashima M, Yamamoto K, Tokuma Y, et al.: Comparative pharmacokinetic/ pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans. Eur J Drug Metab Pharmacokinet 1998, 23: 19-26.
36. Lind T, Rydberg L, Kyleback A, et al.: Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000, 14: 861-867.
37. Landes BD, Petite JP, Flouvat B: Clinical pharmacokinetics of lansoprazole. Clin Pharmacokinet 1995, 28: 458-470.
38. Huber R, Hartmann M, Bliesath H, et al.: Pharmacokinetics of pantoprazole in man. Int J Clin Pharmacol Ther 1996, 34: 185-194.
39. Gerloff J, Mignot A, Barth H, et al.: Pharmacokinetics and absolute bioavailability of lansoprazole. Eur J Clin Pharmacol 1996, 50: 293-297.
40. Klotz U: Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: A review of a special problem. Int J Clin Pharmacol Ther 2006, 44: 297-302.
41. Sjovall H, Bjornsson E, Holmberg J, et al.: Pharmacokinetic study of esomeprazole in patients with hepatic impairment. Eur J Gastroenterol Hepatol 2002, 14: 491-496.
42. Bell NJ, Burget D, Howden CW, et al.: Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992, 51(Suppl 1): 59-67.
43. Pantoflickova D, Dorta G, Ravic M, et al.: Acid inhibition on the first day of dosing: Comparison of four proton pump inhibitors. Aliment Pharmacol Ther 2003, 17: 1507-1514.
44. Miner P Jr, Katz PO, Chen Y, et al.: Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: A five-way crossover study. Am J Gastroenterol 2003, 98: 2616-2620.
45. Kalaitzakis E, Bjornsson E: A review of esomeprazole in the treatment of gastroesophageal reflux disease (GERD). Ther Clin Risk Manag 2007, 3: 653-663.
46. Blum RA, Shi H, Karol MD, et al.: The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion. Clin Ther 1997, 19: 1013-1023.
47. Tolman KG, Sanders SW, Buchi KN, et al.: The effects of oral doses of lansoprazole and omeprazole on gastric pH. J Clin Gastroenterol 1997, 24: 65-70.
48. Geus WP, Mulder PG, Nicolai JJ, et al.: Acid-inhibitory effects of omeprazole and lansoprazole in Helicobacter pylori-negative healthy subjects. Aliment Pharmacol Ther 1998, 12: 329-335.
49. Janczewska I, Sagar M, Sjostedt S, et al.: Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease. Scand J Gastroenterol 1998, 33: 1239-1243.
50. Hartmann M, Theiss U, Huber R, et al.: Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole. Aliment Pharmacol Ther 1996, 10: 359-366.
51. Galmiche JP, Bruley Des Varannes S, et al.: Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: Effects on intragastric pH and comparison with esomeprazole in healthy volunteers. Aliment Pharmacol Ther 2004, 19: 655-662.
52. Hunt RH, Armstrong D, James C, et al.: Effect on intragastric pH of a PPI with a prolonged plasma half-life: Comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers. Am J Gastroenterol 2005, 100: 1949-1956.
53. Castell DO, Richter JE, Robinson M, et al.: Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group. Am J Gastroenterol 1996, 91: 1749-1757.
54. Mee AS, Rowley JL: Rapid symptom reliefAin reflux oesophagitis: a comparison of lansoprazole and omeprazole. Aliment Pharmacol Ther 1996, 10: 757-763.
55. Hatlebakk JG, Berstad A, Carling L, et al.: Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Results of a Scandinavian multicentre trial. Scand J Gastroenterol 1993, 28: 224-228.
56. Mulder CJ, Dekker W, Gerretsen M: Lansoprazole 30 mg versus omeprazole 40 mg in the treatment of reflux oesophagitis grade II, III and IVa (a Dutch multicentre trial). Dutch Study Group. Eur J Gastroenterol Hepatol 1996, 8: 1101-1106.
57. Dekkers CP, Beker JA, Thjodleifsson B, et al.: Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group. Aliment Pharmacol Ther 1999, 13: 49-57.
58. Kahrilas PJ, Falk GW, Johnson DA, et al.: Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: A randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000, 14: 1249-1258.
59. Richter JE, Kahrilas PJ, Johanson J, et al.: Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: A randomized controlled trial. Am J Gastroenterol 2001, 96: 656-665.
60. Labenz J, Armstrong D, Lauritsen K, et al.: A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: The EXPO study. Aliment Pharmacol Ther 2005, 21: 739-746.
61. Stedman CAC Barclay ML: Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000, 14: 963-978.
62. ScarpignatT C, Pelosini I: Review article: the opportunities and benefits of extended acid suppression. Aliment Pharmacol Ther 2006, 23(Suppl 2): 23-34.
63. Katz PO, Castell DO, Chen Y, et al.: Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: A randomized, three-way crossover study. Aliment Pharmacol Ther 2004, 20: 399-406.